Source: International Congress 2015 – Resistance to therapy in lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Brussels, Belgium). Resistance to chemotherapy in lung cancer. International Congress 2015 – Resistance to therapy in lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Chemotherapy for small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Chemotherapy in nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=218 Year: 2001 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Adjuvant therapy in NSCLC Source: Annual Congress 2007 - Clinical year in review Year: 2007 Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Survival of elderly patients with non-small lung cancer tretaed with combined chemotherapy and radiotherapy Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 244–259 Year: 2009 Is there any place for perioperative radiation therapy? Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004